Director at CytomX (NASDAQ: CTMX) awarded 59,000 stock options

Rhea-AI Filing Summary

CytomX Therapeutics director Matthew P. Young received a grant of stock options representing rights to buy 59,000 shares of common stock at an exercise price of $2.96 per share.

All 59,000 option shares will vest in full on the earlier of the first anniversary of the grant date or the 2027 Annual Meeting of CytomX stockholders, as long as he continues serving as a director until that vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Young Matthew P.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	59,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 59,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 59,000 shares Exercise price: $2.96 per share Post-grant derivative holdings: 59,000 options +1 more

4 metrics

Option grant size 59,000 shares Stock Option (Right to Buy) granted to director

Exercise price $2.96 per share Conversion or exercise price of stock option

Post-grant derivative holdings 59,000 options Total options held following transaction

Option expiration June 16, 2036 Expiration date of granted stock options

Key Terms

Stock Option (Right to Buy), grant/award acquisition, conversion or exercise price, Annual Meeting of the Issuer's stockholders, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

grant/award acquisition financial

"transaction_action: grant/award acquisition"

conversion or exercise price financial

"conversion_or_exercise_price: 2.9600"

Annual Meeting of the Issuer's stockholders financial

"earlier of the first anniversary ... or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders"

continuous service as a director financial

"assuming continuous service as a director until such vesting date"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/22/2026 - 04:52 PM Accepted by SEC EDGAR 06/22/2026 - 04:52 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Young Matthew P.

(Last) (First) (Middle)

C/O CYTOMX THERAPEUTICS, INC.

151 OYSTER POINT BLVD., STE. 400

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CytomX Therapeutics, Inc. [ CTMX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.96	06/17/2026		A		59,000		(1)	06/16/2036	Common Stock	59,000	$0	59,000	D

Explanation of Responses:

1. 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.

	/s/ Christopher Ogden, as Attorney-in-Fact for Matthew P. Young	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did CytomX (CTMX) report for Matthew P. Young?

CytomX reported that director Matthew P. Young received a grant of stock options for 59,000 shares of common stock. These options were granted at an exercise price of $2.96 per share as part of his compensation for board service.

What is the size and exercise price of the new CytomX (CTMX) stock options?

The grant covers options on 59,000 shares of CytomX common stock at an exercise price of $2.96 per share. This gives the director the right to buy shares at that fixed price once the options vest.

When do Matthew P. Young’s CytomX (CTMX) stock options vest?

The options vest 100% on the earlier of the first anniversary of the grant date or the date of the 2027 Annual Meeting of CytomX stockholders. Vesting requires his continuous service as a director through that date.

What does the Form 4 say about Matthew P. Young’s holdings after this CytomX grant?

After the transaction, the Form 4 shows Matthew P. Young holding 59,000 stock options directly. These options are derivatives that can be exercised into shares of common stock once they have vested under the stated terms.

Is this CytomX (CTMX) Form 4 an open-market buy or a compensation grant?

This Form 4 reflects a compensation-related grant, not an open-market purchase. The transaction code “A” and description identify it as a grant or award acquisition of stock options granted at a $2.96 exercise price.